Sovaldi OK'd for marketing throughout European Union Healio The approval covers use of Sovaldi with ribavirin or with ribavirin and pegylated interferon for 12 to 24 weeks among HCV patients with genotypes 1-6 and for use with ribavirin until liver transplantation for HCV patients awaiting transplant, the ... |
